Riskpilot← Back to searchSign inGet full accessEkenhälsan Rewell AB
ABActiveOrg 5567849004Ekenleden 15 AMedical specialists activities · NACE 8622Est. 20091-4 employees
Revenue 2024
SEK 7,1M
-11% vs 2023
EBITDA margin
29.4%
+1210% vs 2023
Equity ratio
18.3%
Financial strength
Net profit 2024
SEK -12K
+70% vs 2023
| Revenue | SEK 7,1M | -11% |
| EBITDA | SEK 2,1M | +1210% |
| Net profit | SEK -12K | +70% |
| Total assets | SEK 1,8M | +46% |
| Equity | SEK 325K | -4% |
| Employees | — | — |
Legal name
Ekenhälsan Rewell AB
Org number
5567849004
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
1 juli 2009
Share capital
SEK 100 000
Employees
1-4
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är att bedriva hälso- och sjukvård jämte därmed förenlig verksamhet.
Address
Ekenleden 15 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 667 | 10 555 | 10 905 | 8 009 | 7 108 |
| Staff expenses | — | — | −6 494 | — | −2 356 |
| EBITDA | 3 120 | 1 332 | 159 | −188 | 2 088 |
| Depreciation & amort. | −161 | −23 | −20 | −13 | −13 |
| EBIT | 2 959 | 1 309 | 139 | −201 | 2 075 |
| Net financials | — | 61 | −0 | 11 | 4 |
| Profit before tax | 4 004 | 1 069 | 139 | −40 | −12 |
| Tax | −863 | −222 | −29 | −0 | — |
| Net profit | 3 141 | 847 | 109 | −40 | −12 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 485 | 2 590 | 2 250 | 1 215 | 1 776 |
| Equity | 3 840 | 968 | 377 | 337 | 325 |
| Long-term debt | 0 | 0 | — | 0 | — |
| Short-term debt | 1 644 | 1 322 | 1 573 | 728 | 1 451 |
| Total debt | 1 644 | 1 322 | 1 573 | 728 | 1 451 |
EBITDA margin
29.4%
This company
15.8%
Market median
+86% vs market
20202024
Equity ratio
18.3%
This company
38.2%
Market median
-52% vs market
20202024
Return on equity
-3.6%
This company
18.4%
Market median
-120% vs market
20202024
Net profit margin
-0.2%
This company
8.1%
Market median
-102% vs market
20202024
Asset turnover
4.00×
This company
1.12×
Market median
+257% vs market
20202024
Debt / equity
4.47×
This company
0.62×
Market median
-621% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PK Chief Executive Officer | Chief Executive Officer | 2024 |
HP | Audit | 2023 |
| Former (3) | ||
LK Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 – 2022 |
KJ Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
AK Chief Auditor | Chief Auditor | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rewell Medical AB
Ekenhälsan Rewell AB Board members of Ekenhälsan Rewell AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Kristin Meisel | Deputy Chief Executive Officer | 0 companies |
| Pär Karl Axel Svensson | Chief Executive Officer | 0 companies |
| Karl Jonas Thörnholm | Chief Executive Officer | 0 companies |
| Anna Karin Sofia Niklasson | Chief Auditor | 0 companies |
| Hans Peter Gustafsson | Audit | 0 companies |
| Rolf Tomas Meisel | Deputy Board Member | 0 companies |
| Filip Weintraub | Deputy Board Member | 0 companies |